Search

everythinglearnresearchcommunity

for

Search:↓

The method effectively measures drug impact on DHT levels in prostate treatments.

Obese women with PCOS have lower vitamin D levels.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

Serum triglyceride levels are not linked to prostate cancer risk.

Testosterone implants in women require pharmacological dosing to be effective and are generally safe and well-tolerated.

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

Women with PCOS have higher irisin levels, which may affect their metabolism and hormones.

Hair analysis can somewhat track past testosterone levels but is influenced by factors like hair washing, growth rate, sex, and hair color.

Men with male pattern baldness may have a higher risk of heart disease due to increased levels of a specific lipid in their blood.

Postmenopausal women with hyperandrogenism didn't have better metabolic health even after their testosterone levels became normal.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Higher androgen levels are linked to more severe hair growth in hirsute women.

High testosterone levels in 20% of the women studied may indicate PCOS, while 80% had low levels with potential health impacts.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Testosterone therapy in transgender men has both desired effects like increased muscle mass and potential health risks such as higher cardiovascular risk.

Hair loss in women not always linked to increased oil production; other factors may be involved.

Low vitamin D levels are linked to increased risk of male pattern baldness.

High testosterone increases heart disease risk in women with PCOS.

Spironolactone treatment increases the amount of testosterone available in the body.

Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Finasteride doesn't affect hormone levels in normal men.

The antiandrogen 11α-hydroxyprogesterone effectively reduces skin oil and cholesterol when applied to the skin.

Method accurately measures finasteride in tablets using finasteride-BSA interaction.

Men and premenopausal women in Korea show different patterns in iron and vitamin D levels, with no clear pattern for postmenopausal women.

The risks of testosterone implants in women outweigh the benefits.

Segmental hair analysis can track testosterone over time but needs adjustments for sex, hair color, and washing frequency.

A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.

Testosterone therapy seems safe for postmenopausal women for a few years, but more research is needed for long-term effects.

Testosterone and DHEA can benefit women's health but must be prescribed carefully due to potential risks.